E-mail Updates- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Slides: 1–12 of 72
Background: Juvenile Idiopathic Arthritis
Background: Rheumatoid Factor Test
Background: Cyclic-Citrullinated Peptide Antibody Test
DMARDs for Treating JIA (2 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
Controlled Studies in This CER: Adding Biologic DMARDs to JIA Treatment (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | polyarticular | pauciarticular | oligoarticular | systemic onset | etanercept | infliximab | IVIG | intravenous immunoglobulin | methotrexate
Results: Adding Biologic DMARDs to JIA Treatment (Methotrexate Permitted)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | polyarticular | pauciarticular | oligoarticular | systemic onset | etanercept | infliximab | abatacept | adalimumab | anakinra | tocilizumab | etanercept | IVIG | intravenous immunoglobulin | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR
Summary of Results: Adding Biologic DMARDs to JIA Treatment (Methotrexate Permitted)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR
Meta-analysis of Discontinuation Trials of Biologic DMARDs
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | anti-inflammatory | polyarticular | pauciarticular | oligoarticular | systemic onset | etanercept | infliximab | abatacept | adalimumab | anakinra | tocilizumab | etanercept | IVIG | intravenous immunoglobulin | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR | randomized discontinuation trial | discontinuation trial | flare | remission
Summary: Nonbiologic and Biologic DMARDs Compared With Conventional Anti-inflammatoryTreatments (1 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR | radiographic
Summary: Nonbiologic and Biologic DMARDs Compared With Conventional Anti-inflammatory Treatment (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR | radiographic | health status | flare
Head-to-Head Studies of DMARDs in This Review
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | D-penicillamine | hydroxychloroquine | sulfasalazine | leflunomide | methotrexate | etanercept | infliximab | polyarticular | pauciarticular | systemic onset | oligoarticular
Results: Head-to-Head Comparisons of DMARDs
Keywords: anti-rheumatic | antirheumatic | biologic DMARD | D-penicillamine | disease-modifying | DMARDs | erythrocyte sedimentation rate | ESR | etanercept | health status | hydroxychloroquine | infliximab | JCA | JIA | JRA | juvenile rheumatoid arthritis | leflunomide | methotrexate | non-biologic DMARD | nonbiologic DMARD | oligoarticular | parent global assessment | pauciarticular | physician global assessment | polyarticular | radiographic progression | rheumatic | sulfasalazine | systemic onset | TNF-alpha blockers | juvenile idiopathic arthritis
Your slide tray is being processed.
